Immunic, Inc. (IMUX)
| Market Cap | 108.68M +22.7% |
| Revenue (ttm) | n/a |
| Net Income | -111.57M |
| EPS | -4.00 |
| Shares Out | 13.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 121,786 |
| Open | 8.09 |
| Previous Close | 8.19 |
| Day's Range | 7.95 - 8.19 |
| 52-Week Range | 5.06 - 17.43 |
| Beta | 1.45 |
| Analysts | Strong Buy |
| Price Target | 43.09 (+440.99%) |
| Est. Earnings | Nov 12, 2026 |
About IMUX
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patien... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for IMUX stock is "Strong Buy." The 12-month stock price target is $43.09, which is an increase of 440.99% from the latest price.
News
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
– Four Accepted Abstracts Further Characterize Investigational Vidofludimus Calcium's Profile in Multiple Sclerosis Across Long-Term Disability Outcomes, EBV-Related Immune Activity and Cognition, Nov...
Immunic Transcript: R&D Day 2026
Vidofludimus calcium is advancing through pivotal phase III trials in relapsing MS, targeting both inflammatory and neurodegenerative disease mechanisms. The therapy aims to address key unmet needs in a large, dynamic market, with strong safety, tolerability, and commercial positioning. Phase III readouts and an NDA filing are expected within the next year.
Immunic Slides: FY 2026
Immunic has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 9, 2026.
Immunic Slides: Corporate presentation
Immunic has posted slides in relation to its latest quarterly earnings report, which was published on September 4, 2026.
Immunic Slides: Investor presentation
Immunic has posted slides in relation to its latest quarterly earnings report, which was published on September 3, 2026.
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced tha...
Immunic price target raised to $29 from $19 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan raised the firm’s price target on Immunic (IMUX) to $29 from $19 and keeps a Buy rating on the shares ahead of the Phase 3…
Immunic appoints Chitrang Dave as chief data, digital officer
Immunic (IMUX) announced the appointment of Chitrang Dave as chief data and digital officer, effective immediately. Dave will report directly to CEO Erik Lundgren and will serve as a member…
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer
– New C-Suite Role and Appointment Underscore Commitment to Building a Strong, Commercial-Ready Data Ecosystem, in Preparation for Potential NDA Submission and Commercialization – NEW YORK, Sept. 1, 2...
Immunic initiated with an Outperform at Wedbush
Wedbush analyst Martin Fan initiated coverage of Immunic (IMUX) with an Outperform rating and $45 price target Immunic is a clinical-stage biopharmaceutical company developing immune modulators for im...
Immunic Earnings release: Q2 2026
Immunic released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Immunic Quarterly report: Q2 2026
Immunic has published its Q2 2026 quarterly earnings report on August 11, 2026.
Immunic reports Q2 EPS (80c), consensus ($1.16)
“During the second quarter, we continued to execute across our late-stage development priorities as we advance toward what we believe will be a transformational period for Immunic (IMUX),” said Erik…
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as ND...
Immunic Appoints Elena Ridloff to Board of Directors
– Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in Relapsing Multiple Sclerosis as well as ...
Immunic Slides: Investor presentation
Immunic has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.
Immunic to Participate in Investor Conferences in July
NEW YORK, July 9, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced pa...
Immunic to Participate in Investor, Industry and Scientific Conferences in June
NEW YORK, June 10, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced pa...
Immunic Slides: Corporate presentation
Immunic has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Immunic Proxy statement: Proxy filing
Immunic filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis – – Additional CALLIPER Data Further Highligh...
Immunic CEO Daniel Vitt to step down, Erik Lundgren to succeed
Immunic (IMUX) announced the appointment of Erik Lundgren as CEO, effective May 22, with employment beginning on June 1. Lundgren succeeds Daniel Vitt, who will retain responsibility for scientific st...
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
– Proven Leader with Deep Multiple Sclerosis Expertise; Played Key Role in the Launch of Ocrevus® – – Will Leverage Senior Global Executive and Commercial Experience to Support Immunic's Transition To...
B. Riley cuts Immunic target, sees ‘compelling entry point’
B. Riley analyst William Wood lowered the firm’s price target on Immunic (IMUX) to $27 from $40 and keeps a Buy rating on the shares. The firm says the shares…
Immunic appoints Michael Bonney as chair
Immunic (IMUX) announced the appointment of Michael Bonney as chair of its board of directors, effective May 16. Simona Skerjanec will transition from interim chairperson to continue serving as a…